Resistance to Targeted Therapies in Breast Cancer [electronic resource] / edited by Jenifer R. Prosperi.
Вид матеріалу:
Текст Серія: Resistance to Targeted Anti-Cancer Therapeutics ; 16Публікація: Cham : Springer International Publishing : Imprint: Springer, 2017Видання: 1st ed. 2017Опис: XV, 184 p. 12 illus. online resourceТип вмісту: - text
- computer
- online resource
- 9783319701424
- 614.5999 23
- RC261-271
ЕКнига
Списки з цим бібзаписом:
Springer Ebooks (till 2020 - Open Access)+(2017 Network Access))
|
Springer Ebooks (2017 Network Access))
Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells – The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. .
Available to subscribing member institutions only. Доступно лише організаціям членам підписки.
Online access from local network of NaUOA.
Online access with authorization at https://link.springer.com/
Онлайн-доступ з локальної мережі НаУОА.
Онлайн доступ з авторизацією на https://link.springer.com/
Немає коментарів для цієї одиниці.